Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 147

Similar articles for PubMed (Select 24302608)

1.

The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study.

Locatelli F, Spasovski G, Dimkovic N, Wanner C, Dellanna F, Pontoriero G.

Nephrol Dial Transplant. 2014 May;29(5):1061-73. doi: 10.1093/ndt/gft476. Epub 2013 Dec 2.

2.

Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial.

Locatelli F, Dimkovic N, Spasovski G.

Nephrol Dial Transplant. 2013 Jul;28(7):1874-88. doi: 10.1093/ndt/gft064. Epub 2013 Apr 21.

3.

Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.

Chen N, Wu X, Ding X, Mei C, Fu P, Jiang G, Li X, Chen J, Liu B, La Y, Hou F, Ni Z, Fu J, Xing C, Yu X, Huang C, Zuo L, Wang L, Hunter J, Dillon M, Plone M, Neylan J.

Nephrol Dial Transplant. 2014 Jan;29(1):152-60. doi: 10.1093/ndt/gft232. Epub 2013 Oct 22.

PMID:
24151017
5.

Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients.

Locatelli F, Dimkovic N, Spasovski G.

Expert Opin Pharmacother. 2014 Jul;15(10):1475-88. doi: 10.1517/14656566.2014.928285. Review.

PMID:
24914480
6.

Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability.

de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, Scholz C, Ponce P, Passlick-Deetjen J.

Nephrol Dial Transplant. 2010 Nov;25(11):3707-17. doi: 10.1093/ndt/gfq292. Epub 2010 Jun 7.

8.

Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.

Ahmadi F, Shamekhi F, Lessan-Pezeshki M, Khatami MR.

Saudi J Kidney Dis Transpl. 2012 Sep;23(5):934-8. doi: 10.4103/1319-2442.100865.

9.
10.

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.

Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF.

Am J Kidney Dis. 2009 Oct;54(4):619-37. doi: 10.1053/j.ajkd.2009.06.004. Epub 2009 Aug 18. Review.

PMID:
19692157
11.

Dyslipidemia in chronic kidney disease: randomized controlled trial of colestilan versus simvastatin in dialysis patients.

Wanner C, März W, Varushchanka A, Apanasovich N, Dosta N, Yakubtsevich R, Locatelli F.

Clin Nephrol. 2014 Sep;82(3):163-72.

PMID:
25079861
12.

A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.

Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM; PA21 Study Group.

Kidney Int. 2014 Sep;86(3):638-47. doi: 10.1038/ki.2014.58. Epub 2014 Mar 19.

13.

Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study.

Locatelli F, Dimkovic N, Pontoriero G, Spasovski G, Pljesa S, Kostic S, Manning A, Sano H, Nakajima S.

Nephrol Dial Transplant. 2010 Feb;25(2):574-81. doi: 10.1093/ndt/gfp445. Epub 2009 Sep 7.

14.

Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.

Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan-Taber S, Heaton J, Duggal A, Kalra PA.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1125-30. doi: 10.2215/CJN.05161107. Epub 2008 May 1.

15.

Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.

Gallieni M, Cozzolino M, Carpani P, Zoni U, Brancaccio D.

J Nephrol. 2001 May-Jun;14(3):176-83.

PMID:
11439741
16.

Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.

Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S.

Nephrol Dial Transplant. 2009 Jan;24(1):278-85. doi: 10.1093/ndt/gfn488. Epub 2008 Sep 27.

17.

Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.

Goldberg DI, Dillon MA, Slatopolsky EA, Garrett B, Gray JR, Marbury T, Weinberg M, Wombolt D, Burke SK.

Nephrol Dial Transplant. 1998 Sep;13(9):2303-10.

18.
19.

Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.

Almirall J, Lopez T, Vallve M, Ruiz A, Llibre J, Betriu A.

Nephron Clin Pract. 2004;97(1):c17-22.

PMID:
15153763
20.

Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.

Tonelli M, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, Manns B; Alberta Kidney Disease Network.

Nephrol Dial Transplant. 2007 Oct;22(10):2856-66. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk